***Background.*** High-dose inactivated influenza vaccine (IIV-HD) induces higher antibody responses and provides improved protection against influenza illness compared to a standard-dose vaccine (IIV-SD) in older adults. We evaluated its impact on disease modulation.

***Methods.*** A multicenter, randomized, double-blind, active-controlled trial compared IIV-HD (60 µg of hemagglutinin \[HA\] per strain) to IIV-SD (15 µg of HA per strain) in adults ≥65 years (NCT01427309). Participants contacted their study site if they experienced a respiratory illness (RI). A nasopharyngeal swab was to be collected within 5 days of RI onset for laboratory confirmation of influenza (culture and/or a polymerase chain reaction). Information was collected on illness duration and symptoms, as well as on the occurrence of cardio-respiratory events and hospitalizations within 30 days of RI onset. Cardio-respiratory events and hospitalizations were attributed to influenza by three blinded physician reviewers.

***Results.*** 31,989 participants were enrolled (15,991 and 15,998 randomized to IIV-HD and IIV-SD, respectively). A laboratory-confirmed influenza RI occurred in 316 IIV-HD vaccinees (1.98%) and 387 IIV-SD vaccinees (2.42%). Median duration of illness was 11 (inter quartile range \[IQR\]: 8, 19) and 14 (IQR: 8, 21) days for IIV-HD and IIV-SD, respectively (p = 0.003). Fewer symptoms occurred among cases in the IIV-HD group compared to those in the IIV-SD group (p = 0.04; non-parametric test). Of participants with a laboratory-confirmed influenza RI, 136 influenza-attributed cardio-respiratory events occurred within 30 days of illness onset: 54 (17.1%) for IIV-HD and 82 (21.2%) for IIV-SD group (relative risk \[RR\] 0.81; 95% CI 0.59, 1.10). Ten hospitalizations attributed to influenza occurred within 30 days of illness onset: 4 (1.27%) for IIV-HD and 6 (1.55%) for IIV-SD (RR: 0.82; 95% CI: 0.23, 2.87).

***Conclusion.*** IIV-HD was associated with significantly shorter duration and fewer symptoms for laboratory-confirmed influenza RI compared to IIV-SD. Rates of cardio-respiratory events and hospitalizations within 30 days of laboratory-confirmed influenza were lower after IIV-HD but the number of cases was too few for comparisons to reach statistical significance.
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